The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
I think it's as simple as this:
Short-term down-side: we're not the first or sole answer to Covid (which put some of us in £50 SP dreamland). SP has hit a low, and could even have a bit further to fall if all we hear is vaccines, vaccines, vaccines.
Mid-term up-side: once P3 is approved, we'll be needed across the world in 2021, as global vaccination will take time.
Long-term up-side: future viruses, COPD, flu, asthma etc...
However, I wonder if we'll get a EUA in the next few weeks, once home trials and or the first half of P3 data gets included alongside the P2 data set? (with the P2 peer review to give credibility)
No one should mind certain contrarians on this BB - the ones who provide some interesting information and evidence to back up their point of view. However, I never see Rob do this. So Rob, I suggest you come back with some more detail to back up your point of view. Come on give it a go...
I caught Covid back in March. Average symptoms. I signed up for the plasma donation trial soon after. I finally got called up to test my antibody levels a couple of weeks ago. Findings were that I had Covid antibodies in my body, but not enough to be a donor. Sample of one to back up the hypothesis that antibodies might not necessarily stick around in your body for 6 months. Although maybe the resistance is now in my B and T cells?
After emergency approval and beyond:
- All those with Covid who haven't had a vaccine yet
- All those in future with Covid who haven't a had vaccine yet
- Countries around the world stock-piling for therapeutics for Covid before everyone is vaccinated
- All those in future with Covid who've had a vaccine, but it hasn't worked
- Stockpiles around the world as a precaution for future potential pandemics
- COPD potential.
- Influenza?
- Other potential viruses?
Anything else I've missed?
All that with a current market cap of £208 Million
I avoided filtering in the past in order to see the odd contrarian post. But now there's someone who needs his BB Oxygen starved from him. You all know who it is. So I'd suggest that those who haven't used the filter option before make one commitment today / tomorrow to start using it, if only for this one true idiot. Cheers Dudio.
Had a little go at Monday day-trading with a 1/3 of my SNG shares, just to bring my average down a bit (as it's higher than most on here I expect) - trying to sell at the early Monday peak and then buy back later on. Despite getting a bit lucky with the Moderna fuelled dip, I hated being out and said to myself that I'll just stick from now on.
Gejus. True sounds just like Eva last week - and then she missed out on buying SNG at 90 and selling at 140 - a potential 55% gain in a few days. However, at least she achieved that elsewhere (whatever the stock was called). True... sure there's value elsewhere. Go check out some pot luck mining stock.
The company currently has data on 100 individuals. And are recruiting 900 more for Phase 3. Does anyone have a view at which stage within phase 3 emergency approval might be granted?
The statistical confidence levels will improve dramatically I would think when the sample increases from 100 to 200. Is having a sample of 1000 there to get that confidence level up to a figure of near certainty (e.g 99%) or to also gain more insight into the likes of when and with whom it works most effectively, dosage levels etc...?
I'm also assuming that one reason for staging the trial in 20 countries is to get on the radar of different countries / regions approval boards?
I just have a hunch that we might get early approval, way before the official end of Phase 3.
Scorpio, relying on dodgy A' Level French from quite a long time ago.. but starts by saying that if you Google Interferon beta and Covid you'll find the Synairgen study... then goes into the details about the two groups and the effects of Synairgen vs the placebo.